RESUMEN
Isolated rapid-eye-movement sleep behavior disorder (iRBD) is considered to be a prodromal stage of α-synucleinopathies, providing an important period for investigating biomarkers of conversion risk and potentially disease-modifying intervention. Many previous studies investigating biomarkers in patients with iRBD have focused on different domains including clinical, body fluid and imaging. Due to their direct response to the pathological changes of brain and advantaged accessibility, body fluid markers have become promising potential biomarkers. These studies have involved different molecules related to different pathogenic mechanisms with poor consistency of results. In this paper, a review of previous work on body fluid markers in patients with iRBD is presented.